safetyriskБезопасность и риск фармакотерапииSafety and Risk of Pharmacotherapy2312-78212619-1164Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)safetyrisk-291Research ArticleОБЗОРЫ И ОРИГИНАЛЬНЫЕ СТАТЬИREVIEWS AND ORIGINAL ARTICLESЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ ПЕРЕДОВОЙ ТЕРАПИИ ПРИ ЛЕЧЕНИИ ВОЗРАСТНОЙ МАКУЛЯРНОЙ ДЕГЕНЕРАЦИИTHE EFFICACY AND SAFETY PROFILE OF ADVANCED THERAPY MEDICINAL PRODUCTS IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATIONАляутдинР. Н.AlyautdinR. N.РомановБ. К.RomanovB. K.ЛепахинВ. К.LepakhinV. K.МеркуловВ. А.MerculovV. A.МироновА. Н.MironovN. A.Федеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения» Министерства здравоохранения Российской ФедерацииРоссияScientific Centre for Expert Evaluation of Medicinal Products Russian FederationRussian Federation201430052022011217Copyright © Аляутдин Р.Н., Романов Б.К., Лепахин В.К., Меркулов В.А., Миронов А.Н., 20222022Аляутдин Р.Н., Романов Б.К., Лепахин В.К., Меркулов В.А., Миронов А.Н.Alyautdin R.N., Romanov B.K., Lepakhin V.K., Merculov V.A., Mironov N.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.risksafety.ru/jour/article/view/291

Возрастная макулярная дегенерация является основной причиной нарушения зрения. В обзоре представлены современные лекарственные средства, используемые для лечения макулярной дегенерации. Сопоставление эффективности и профиля безопасности бевацизумаба, ранибизумаба, афлиберцепта и пегаптаниба позволяет заключить, что каждое из этих соединений имеет собственные достоинства и недостатки. Дальнейшее исследование клинической эффективности позволит выработать рациональные схемы их применения.

Age-related macular degeneration is the main cause of loss of sight in the world. This review presents a current view on modern drugs used for the treatment of macular degeneration. A comparison effectiveness and safety profile of bevacizumab, ranibizumab, and pegaptanib aflibercept enables us to conclude that each of these compounds has its own advantages and disadvantages. Further study will develop rational schemes of their application.

передовая терапиялекарственные средствавозрастная макулярная дегенерациябевацизумабранибизумабафлиберцептпегаптанибadvanced therapymedicinal productsage-related macular degenerationbevacizumabranibizumabpegaptanibafliberceptReferencesHadrill M. Macular degeneration treatment [webpage on the Internet]. Http://www.allaboutvision.comHadrill M. Macular degeneration treatment [webpage on the Internet]. Http://www.allaboutvision.comThomas M., Mousa S.S., Mousa S.A. Comparative effectiveness of aflibercept for treatment of patients with neovascular age-related macular degeneration.// Clin. Ophthal., 2013,7, 495-501Thomas M., Mousa S.S., Mousa S.A. Comparative effectiveness of aflibercept for treatment of patients with neovascular age-related macular degeneration.// Clin. Ophthal., 2013,7, 495-501Stewart M.W. Clinical and differential utility of VEGF inhibitors in wet age –related vacular degeneration.// Clin. Ophthal., 2012, 6, 1175-1186Stewart M.W. Clinical and differential utility of VEGF inhibitors in wet age –related vacular degeneration.// Clin. Ophthal., 2012, 6, 1175-1186Kvanta A. Ocular angiogenesis: the role of growth factors.// Acta Ophthalmol. Scand., 2006, 84, 282-288Kvanta A. Ocular angiogenesis: the role of growth factors.// Acta Ophthalmol. Scand., 2006, 84, 282-288Penn J.S., Madan A., Caldwell L.D. Vascular endothelial growth factor in eye disease. // Prog. Retin. Eye Res., 2008, 27, 331-371Penn J.S., Madan A., Caldwell L.D. Vascular endothelial growth factor in eye disease. // Prog. Retin. Eye Res., 2008, 27, 331-371Fournier E., Birnbaum D., Borg J.P. Receptors for factors of the VEGF.// Bull. Cancer., 1997, 84, 397-405Fournier E., Birnbaum D., Borg J.P. Receptors for factors of the VEGF.// Bull. Cancer., 1997, 84, 397-405Smith L.E., Kopchick J.J., Chen W. Essential role of growth hormone in iscemis–induced retinal neovascularisation. Science, 1997,276, 1706-1709Smith L.E., Kopchick J.J., Chen W. Essential role of growth hormone in iscemis–induced retinal neovascularisation. Science, 1997,276, 1706-1709Bylsma G.W., Guymar R.H. Treatment of age-related macular degeneration.// Clin. Exp. Optom., 2005, 88, 322-334Bylsma G.W., Guymar R.H. Treatment of age-related macular degeneration.// Clin. Exp. Optom., 2005, 88, 322-334Tsutsumi C., Sonoda K.H., Egashira K. et al. The critical role of ocular infiltrating macrophages in the development of choroidal neovascularisation.// J. Leukos. Biol. 2003, 74, 25-32Tsutsumi C., Sonoda K.H., Egashira K. et al. The critical role of ocular infiltrating macrophages in the development of choroidal neovascularisation.// J. Leukos. Biol. 2003, 74, 25-32Folkman J. Angiogenesis: an organizing principle for drug discovery?// Nat Rev Drug Discov., 2007,6,273-286.Folkman J. Angiogenesis: an organizing principle for drug discovery?// Nat Rev Drug Discov., 2007,6,273-286.Sanro de Falco. Antiangiogenesis therapy: an update after the first decade.// Korean J Intern Med 2014, 29,1-11Sanro de Falco. Antiangiogenesis therapy: an update after the first decade.// Korean J Intern Med 2014, 29,1-11Malhotra M., Majumdar D.K. Permeation through cornea. Indian J. Exp. Biol. 2001; 39: 11–24Malhotra M., Majumdar D.K. Permeation through cornea. Indian J. Exp. Biol. 2001; 39: 11–24Kawakami S., Yamamura K., Mukai T., et al: Sustained ocular delivery of tilisolol to rabbits after topical administration or intravitreal injection of lipophilic prodrug incorporated in liposomes. J. Pharm. Pharmacol. 2001; 53: 1157–61.Kawakami S., Yamamura K., Mukai T., et al: Sustained ocular delivery of tilisolol to rabbits after topical administration or intravitreal injection of lipophilic prodrug incorporated in liposomes. J. Pharm. Pharmacol. 2001; 53: 1157–61.Barar J., Javadzadeh A.R., Omidi Y. Ocular novel drug delivery: impacts of membranes and barriers. Expert. Opin. Drug Deliv. 2008; 5(5): 567–81Barar J., Javadzadeh A.R., Omidi Y. Ocular novel drug delivery: impacts of membranes and barriers. Expert. Opin. Drug Deliv. 2008; 5(5): 567–81Р. Н. Аляутдин, И. Н. Иежица, Р. Агарвал (R. Agarwal). Транспорт лекарственных средств через роговицу глаза. Вестник офтальм. 2014, №2Р. Н. Аляутдин, И. Н. Иежица, Р. Агарвал (R. Agarwal). Транспорт лекарственных средств через роговицу глаза. Вестник офтальм. 2014, №2Lallemand F, Bayeaens O, Besseghir K et al. Cyclosporine delivery to the eye: pharmaceutical challenge. Eur. Pharm. Biopharm. 2003; 56: 307-319.Lallemand F, Bayeaens O, Besseghir K et al. Cyclosporine delivery to the eye: pharmaceutical challenge. Eur. Pharm. Biopharm. 2003; 56: 307-319.Р.Н. Аляутдин. Транспорт лекарственных веществ через гемато-энцефалический барьер: линия Мажино или волшебный Сезам?// Молек.мед., 2013, №3, 12-17Р.Н. Аляутдин. Транспорт лекарственных веществ через гемато-энцефалический барьер: линия Мажино или волшебный Сезам?// Молек.мед., 2013, №3, 12-17Bylsma J.V., Guymer R.H. Treatment of age-related macular degeration.//Clin. Exp. Optom. 2005, 234, 117-120Bylsma J.V., Guymer R.H. Treatment of age-related macular degeration.//Clin. Exp. Optom. 2005, 234, 117-120P. Ventrice, C. Leporini, J/F. Aloe, Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases.// .J Pharmacol Pharmacother.2013; 4(Suppl1): S38–S42P. Ventrice, C. Leporini, J/F. Aloe, Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases.// .J Pharmacol Pharmacother.2013; 4(Suppl1): S38–S42A. Ozkaya, Z. Alkin, Y. Karakucuk. Bevacizumab versus Ranibizumab on as-needed treatment regimen for neovascular agerelated macular degeneration in turkish patients.// ISRN Ophthalmol. 2013; 2013: 151027.A. Ozkaya, Z. Alkin, Y. Karakucuk. Bevacizumab versus Ranibizumab on as-needed treatment regimen for neovascular agerelated macular degeneration in turkish patients.// ISRN Ophthalmol. 2013; 2013: 151027.A. Manna, O. Oyede, B. Ning. Avastin and Lucentis: what do patients know? A prospective questionnaire survey.// JRSM Short Rep. Sep 2013; 4(9): 2042533313484146 22. K. K. Ciomur, J. Berlin. Aflibercept. // Clin.Cancer.Res., 2013, 19, 1920-1925A. Manna, O. Oyede, B. Ning. Avastin and Lucentis: what do patients know? A prospective questionnaire survey.// JRSM Short Rep. Sep 2013; 4(9): 2042533313484146 22. K. K. Ciomur, J. Berlin. Aflibercept. // Clin.Cancer.Res., 2013, 19, 1920-1925A.V. Lakhin, V.Z. Tarantul, L.V. Gening. Aptamers: problems, solutions, prospects.// Acta Natrure, 2013, №4, 34-43A.V. Lakhin, V.Z. Tarantul, L.V. Gening. Aptamers: problems, solutions, prospects.// Acta Natrure, 2013, №4, 34-43C.A. Trujillo, A.A. Nery, J.M. Martis. Development of the anti-VEGF aptamer to a therapeutic agent for clinical ophthalmology.// Clin. Ophthalmol., 2007, 1, 393-402.C.A. Trujillo, A.A. Nery, J.M. Martis. Development of the anti-VEGF aptamer to a therapeutic agent for clinical ophthalmology.// Clin. Ophthalmol., 2007, 1, 393-402.

The authors declare that there are no conflicts of interest present.